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Abstract 
Objective: Explore the intersection of the Pharmacists’ Patient Care Process (PPCP) and state laws in order to identify laws that may 
impede the delivery of optimal patient care. 
Summary: A review of the PPCP identified six areas in which state laws can limit full pharmacist engagement: 1) ordering and 
interpreting laboratory tests; 2) participating in a collaborative practice agreement; 3) independently prescribing certain medications; 
4) independently adapting medications; 5) administering medications; and 6) effective delegation. A framework is put forth to organize 
how these scope of practice matters are interrelated. 
Conclusion: For pharmacists to fully engage in the PPCP, state laws must enable full participation. By unleashing pharmacists to fully 
engage in the process, patient care delivery and outcomes can be improved, and total health care costs can be reduced. 
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A growing body of evidence demonstrates that when 
pharmacists are fully deployed as part of the health care team, 
patient outcomes improve and total healthcare costs are 
reduced.1 In 2014, pharmacy associations put forth the 
Pharmacists’ Patient Care Process (PPCP), a consensus-based 
document to establish a consistent, stepwise approach for the 
spectrum of pharmacist-delivered services available in any 
practice setting.2 The process consists of five steps: 1) collect; 
2) assess; 3) plan; 4) implement; and 5) follow-up. The entire 
process is rooted in patient-centered care, close collaboration 
with the patient’s broader health care team, and robust 
documentation of services provided.2 
 
The PPCP has been embraced within the profession and is 
gaining traction from public health agencies.3-5 For 
pharmacists to integrate the PPCP into practice, however, the 
profession must work to remove legal barriers that impede 
patient care and prevent pharmacists from fully performing 
steps in the process. State “scope of practice” laws and 
regulations establish what pharmacists are legally authorized 
to perform in practice. We have identified six scope of practice 
activities (Table 1) impacted by laws that lag behind the clinical 
ability of pharmacists, as determined by their education, 
training, experience, and practice environment (e.g., 
community vs. institutional).6 This manuscript will explore the 
intersection of the PPCP and state scope of practice laws in 
order to identify areas that may impede the delivery of optimal 
patient care. 
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State Scope of Practice Restrictions Relevant to Pharmacists’ 
Patient Care Process 
The ‘assess’ and ‘plan’ steps of the PPCP leverage pharmacists’ 
unique, medication-focused professional judgment. 
Specifically, the pharmacist assesses available information 
and, in collaboration with the patient, formulates an 
individualized care plan designed to achieve the patient’s 
health goals. These steps are inherently cognitive in nature and 
we are not aware of any scope of practice restrictions at the 
state level that prevent a pharmacist from performing these 
cognitive steps. We have observed state scope of practice 
restrictions that impact pharmacists’ ability to fully engage in 
the ‘collect,’ ‘implement’ and ‘follow-up’ steps of the PPCP.  
 
Collect 
The ‘collect’ step is the first in the process, and involves the 
pharmacist gathering relevant “subjective and objective 
information about the patient in order to understand the 
relevant medical/medication history and clinical status of the 
patient.” For this step, pharmacists collect information from a 
variety of sources including patient questionnaires, the 
pharmacy management system (e.g., medication histories), 
other healthcare providers, physical assessments, and 
biometric tests, among others. 
 
Pharmacists’ ability to execute on the ‘collect’ step depends, 
in part, on their legal authority to order and interpret 
laboratory tests. Clinical laboratory tests are grouped into 
“waived” or “non-waived” categories by the Food and Drug 
Administration (FDA), based on specified criteria in the Clinical 
Laboratory Improvement Amendments (CLIA).7 Waived tests, 
commonly referred to as CLIA-waived, are simple enough that 
there is a low risk for an incorrect result with proper specimen 
collection. Common examples include tests for hemoglobin 
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A1c, cholesterol, and Hepatitis C. To perform CLIA-waived 
tests, the pharmacy must obtain a CLIA certificate of waiver 
through the relevant state agency. Non-waived testing 
includes both moderate and high complexity testing. Examples 
of non-waived tests include certain tests for prothrombin time, 
used in warfarin clinics; certain liver function tests; and many 
urinalysis tests.8 Unsurprisingly, entities wishing to perform 
non-waived tests are held to more stringent standards 
including biennial inspections and quality metrics related to 
proficiency testing, quality control, and personnel.9  
 
Pharmacies in the U.S. are currently providing CLIA-waived 
and, rarely, non-waived testing. In a May 2015 review, 10,838 
pharmacies held CLIA certificates of waiver—18% of all 
pharmacies nationwide (ranging from 0% to 60% of 
pharmacies within a given state).10-11 The study also found that 
99.85% of pharmacies listed as a laboratory limited their 
testing to CLIA-waived tests only, and thus did not perform any 
non-waived tests.12 While it is unlikely in the short term that 
pharmacies will serve as laboratories of non-waived tests, two 
national pharmacy chains have recently partnered with 
national laboratory companies which may facilitate broader 
testing performed by qualified laboratory personnel outside 
the pharmacy.12-13 
 
To perform laboratory testing, pharmacies must be legally 
authorized to serve as a CLIA laboratory. The 2016 National 
Association of Boards of Pharmacy (NABP) Survey of Law 
included the following question: “May pharmacists administer 
tests?”14 While the question did not differentiate waived vs. 
non-waived tests, 23 states responded “no.”15 However, 
regardless of whether the pharmacy is directly performing 
laboratory tests, pharmacists must have the legal authority to 
order and interpret tests to fully take part in the ‘collect’ step 
of the PPCP. Unfortunately, not all state practice acts allow 
pharmacists to order tests and still more present barriers such 
as requiring a collaborative practice agreement. 
 
Implement 
Similarly, we have identified state scope of practice 
restrictions related to the ‘implement’ step in the process. In 
this step, the pharmacist “implements the care plan in 
collaboration with other health care professionals and the 
patient or caregiver.”2 The PPCP speaks to certain actions that 
the pharmacist may need to take effectively carry out this step, 
including cognitive services such as patient education and self-
management training, and logistical services like scheduling 
follow-up care. The step also includes several items that vary 
by state: 1) initiating, modifying (adapting), and discontinuing 
medication regimens; and 2) administering medications 
(including vaccines). 
 
The initiation or modification of medication therapy 
traditionally occurs under the auspices of a collaborative 
practice agreement (CPA) in most states. A CPA is a formal 
agreement between pharmacists and other healthcare 
providers in which the pharmacist is authorized to perform 
services that are otherwise outside of his or her legal scope of 
practice, but for which the pharmacist is educationally and 
clinically prepared.16 CPAs have been used to allow 
pharmacists to prescribe for acute infections based on 
laboratory test results, such as influenza and strep throat, and 
chronic disease management, such as modifying the dose of 
diabetes medications, among other uses.17-18  
 
Nearly all states allow pharmacists to enter into CPAs, though 
state laws may significantly limit uptake of CPAs by limiting 
which prescribers and pharmacists may enter into an 
agreement, where services may be delivered, and what 
patients or patient populations may be cared for under the 
agreement, among other parameters.19 For example, states 
that limit CPAs to specific patient populations may enable 
services in settings with well-defined patient populations (e.g., 
institutional settings or ambulatory care clinics) while 
significantly impacting their feasibility in community pharmacy 
settings. 
 
Recently, some states have expanded the medications that 
pharmacists may prescribe autonomously without a CPA. To 
date, states have adopted two strategies to do so: statewide 
protocols issued by a state regulatory board, and independent 
prescriptive authority in which the state defers to existing 
clinical guidelines.20-21 The medications that pharmacists can 
currently prescribe independently in certain states have 
typically focused on those that have preventive or short-term 
uses: immunizations, fluoride supplements, opioid 
antagonists, epinephrine auto-injectors, travel medications, 
tobacco cessation medications, and tuberculin (TB) purified 
protein derivative products, among others.22-27 A growing 
number of states have expanded this authority to chronic 
preventive medications, such as hormonal contraceptives.28  
 
Some states have also allowed pharmacists to modestly 
‘adapt’ medications outside of a CPA. Adapting includes 
modifications of quantity (e.g., converting a 30-day supply to a 
90-day supply or extending a one-time refill or short fill) and, 
in a few states, therapeutic substitutions within a drug class in 
outpatient settings.29-30 Therapeutic substitution in 
accordance with a formulary is more common within 
institutional settings.  
 
Implementing a care plan may also include administering a 
medication by any route (oral, topical, sub-dermal, 
subcutaneous, intramuscular, intranasal, etc.) to a patient. 
Pharmacists in all 50 states have the legal authority to 
administer influenza vaccines to at least some patient 
populations, but states vary in their authority as it relates to 
other medications such as injectable antipsychotic 
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medications.30 There are at least 40 states that allow 
pharmacists to administer non-immunizations, though there 
are various levels of restriction in doing so.31 
 
Follow-Up 
Like in the ‘collect’ step, authority to order, administer, and 
interpret laboratory tests is also necessary to develop and 
implement a ‘follow-up’ care plan. In the ‘follow-up’ step, the 
pharmacist “monitors and evaluates the effectiveness of the 
care plan and modifies the plan in collaboration with other 
health care professionals and the patient or caregiver as 
needed.”2 Certain laboratory tests are necessary for 
monitoring disease progression, response to medication 
therapies, and adverse reactions. 
 
Delegation 
Lastly, state scope of practice laws may also limit the ability of 
pharmacists to delegate certain tasks to pharmacy technicians 
and student pharmacists. Studies show that pharmacy 
technicians can safely and effectively perform tasks (that do 
not require clinical judgment) related to the ‘collect,’ 
‘implement,’ and ‘follow-up’ steps. These tasks could include 
performing medication reconciliation or product verification, 
for medications a pharmacist has assessed for clinical 
appropriateness.32-33  
 
Discussion 
A review of the Pharmacists’ Patient Care Process identified six 
areas in which state scope of practice laws can limit full 
pharmacist engagement in activities they are qualified to 
perform: 1) ordering and interpreting laboratory tests; 2) 
participating in a collaborative practice agreement; 3) 
independently prescribing certain medications; 4) 
independently adapting medications; 5) administering 
medications; and 6) effective delegation. Figure 1 represents 
an appropriate pharmacy practice framework, which attempts 
to organize how these scopes of practice matters interrelate. 
 
Collaborative practice authority forms the foundation of the 
framework. CPAs enable pharmacists to provide services that 
are otherwise outside of their state law’s scope of practice, but 
for which they are adequately trained. In some states, CPAs are 
the only way (albeit not ideal) that pharmacists can order or 
interpret tests, prescribe, or administer medications. 
However, some states’ collaborative practice authority is so 
restrictive that there is little use of the authority in practice. 
Though national stakeholder groups have developed policy 
recommendations for appropriate CPA authority, many states 
still have unnecessary restrictions and requirements in place.19  
 
Broad CPA authority, without burdensome regulatory 
restrictions, helps create an elastic scope of practice. This 
flexibility enables pharmacists to practice at the top of their 
clinical ability, despite what their restrictive state scope of 
practice may allow independently. In the short term, CPAs will 
be the primary vehicle through which pharmacists can initiate, 
modify or discontinue medication therapy, especially for 
chronic conditions.  
 
Though not included in the framework, note that some states 
authorize physicians to issue “standing orders” from which 
pharmacists may dispense certain medications. This type of 
authority is related but distinct from CPAs. Because standing 
order provisions are usually drug category specific, they are 
inherently more restrictive than CPA authority and leave no 
room for negotiation at the individual practice level.  
 
The next layer of the framework consists of services that 
pharmacists may provide independently in at least some states 
today. “Independently” (e.g., outside of a CPA) does not mean 
non-collaboratively. As a standard of practice—and consistent 
with the PPCP—all services a pharmacist provides should be 
performed in a coordinated, team-based fashion. CPAs, 
however, require more than collaboration; they require 
permission. To provide services under a CPA, a pharmacist 
must first find a willing collaborator. This has proven 
challenging as the value proposition for a prescriber to enter 
into a CPA is not always aligned for all practice settings due to 
constraints in the medical reimbursement model among other 
considerations. As such, pharmacists must have the 
independent authority to provide services that are within their 
education and training and have inherent value for public 
health and wellbeing. 
 
The independent authority layer starts with ordering and 
interpreting tests, though the activities in this layer are 
interdependent rather than discreet steps. For example, 
independent prescribing of certain medications in some 
instances may either be based on the result of a laboratory test 
(e.g., prescribing an antiviral based on the result of an 
influenza CLIA-waived diagnostic test) or a test may be 
necessary to appropriately monitor a drug therapy-related 
outcome from a pharmacist-prescribed medication. Similarly, 
medication administration may occur in conjunction with, or 
separately from, pharmacist prescribing—especially for 
immunizations. Lastly, adapting a medication could include 
modifying regimens (e.g., change a dose) based on the result 
of a test, though state laws now limit pharmacists to activities 
such as adjusting a quantity or performing limited therapeutic 
substitution. 
 
We anticipate independent prescriptive authority will 
continue to grow—especially for preventive medications and 
those not requiring a diagnosis (e.g. tobacco cessation 
products). Based on the experience of our colleagues in 
Canada, another category ripe for further exploration is “minor 
ailments,” which consists of products for self-limiting 
conditions, such as cold sores, minor acne, and minor wounds, 
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among others. We also see significant potential for closing 
clinical gaps in care based on evidence-based guidelines (e.g. 
statins for patients with diabetes). 
 
Unless (or perhaps until) pharmacist prescriptive authority 
evolves to be more like that of nurse practitioners in many 
states (independent and unrestricted), we see a continued role 
for CPAs. As the base of the framework, CPAs represent not 
only the beginning of pharmacists’ scope expansion but also, 
when enacted with few restrictions and barriers, an 
opportunity for growth and further innovation. As technology, 
the healthcare system, and pharmacy education evolves, there 
may be new opportunities for pharmacist-provided care 
delivery. These new models can be tested – in collaboration 
with physicians and other prescribers – and studied under a 
CPA model. Evidence produced from such experimentation 
can then be used to demonstrate the need for further 
modifications to pharmacist scope provisions. Thus, although 
the authorities within the independent layer of the framework 
will expand, they will not do away with the regulatory benefit 
of CPAs. 
 
The top of the framework consists of effective delegation. 
When states place limitations on what can be delegated, a 
substantial portion of pharmacists’ time may be devoted to 
non-clinical activities that deny pharmacists the time 
necessary to effectively engage in higher order clinical tasks.32-
33 Thus, this is portrayed as the roof of the framework, 
protecting pharmacists’ ability to participate fully in the PPCP. 
If pharmacists are empowered to delegate tasks that can be 
performed safely by support personnel, they can focus on 
providing more patient care services in accordance with the 
Pharmacists’ Patient Care Process. 
 
Although the focus of this paper is on scope of practice 
challenges, we acknowledge that other barriers in the market 
may challenge the integration of some clinical services into 
pharmacists’ workflow—payment, time constraints, access to 
data, etc. These challenges are distinct from issues related to 
whether pharmacists are legally authorized to perform the 
activity and thus outside the scope of this paper.  
 
Conclusion 
For pharmacists to fully engage in the PPCP, state laws must 
enable them to participate in collaborative practice 
agreements; order and interpret laboratory tests; 
independently prescribe, adapt, and administer medications; 
and effectively delegate to support personnel. By enabling 
pharmacists to fully engage in the PPCP, patient care delivery 
and outcomes can be improved, and total health care costs can 
be reduced. 
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Table 1. Brief Summary of Identified Scope of Practice Activities 
 
Scope of Practice 
Activity 
Brief Description PPCP1 Step 
Impacted 
Order and Interpret 
Laboratory Tests 
Laboratory tests may be “waived” or “non-waived” according to CLIA. 
Pharmacies commonly hold CLIA certificates of waiver to provide simply, 
low-risk tests, like those for testing blood glucose, cholesterol, or for 
influenza. Laboratory tests may be used to monitor medication therapy 
outcomes or disease progression. 
 
Collect; Follow-Up 
Participate in 
Collaborative 
Practice 
Agreements (CPA) 
A CPA is a formal agreement between pharmacists and other healthcare 
providers in which the pharmacist is authorized to perform services that 
are otherwise outside of his or her legal scope of practice, but for which 
the pharmacist is educationally and clinically prepared. CPAs are the 
primary vehicle through which pharmacists may initiate, modify, or 
discontinue medications. Though not preferred, in some states CPAs are 
the only current vehicle through which pharmacists can order and 
interpret laboratory tests, adapt medications, or administer medications. 
 
Collect; Implement; 
Follow-Up 
Independently 
Prescribe Certain 
Medications 
Independent prescribing refers to a pharmacist selecting a medication for 
a patient, along with the dosing regimen for a medication without the 
need for a CPA. Some states currently allow pharmacists to independently 
prescribe certain medications, such as hormonal contraceptives or 
tobacco cessation medications. 
 
Implement 
Adapt Medications Adapting a medication is differentiated from independently prescribing in 
that it results in modifying a prescription from another prescriber. Today 
independent adaptation is generally limited to modifying the quantity of a 
prescription (e.g., converting from a 30-day supply to a 90-day supply) or, 
less commonly, engaging in therapeutic substitution. 
 
Implement 
Administer 
Medications 
A pharmacist most commonly administers a medication to a patient by 
injection, though administration encompasses many routes of delivery 
(oral, topical, sub-dermal, subcutaneous, intramuscular, intranasal, etc.).  
 
Implement 
Effective Delegation 
to Support 
Personnel 
Effective delegation involves empowering pharmacists with the discretion 
to delegate tasks to technicians and student pharmacists under their 
supervision. Most states restrict which tasks pharmacists can delegate to 
support personnel, and studies show this may redirect pharmacist time to 
low-value tasks and away from the PPCP. 
 
Collect; Implement; 
Follow-Up 
Cognitive Services Cognitive services such as evaluating medication therapy-related problems 
and formulation of a care plan are not typically restricted by scope of 
practice in states, as professional judgment is inherent in the pharmacists’ 
work. Payment for services continues to be an issue, though this is a 
separate matter from scope of practice. 
 
All steps, though 
particularly the 
Assess and Plan 
steps 
1.PPCP – Pharmacists’ Patient Care Process 
2.CLIA – Clinical Laboratory Improvement Amendments  
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Figure 1. Pharmacist Scope of Practice Framework 
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